GLP-1代谢物GLP-1(9-36)是小鼠和人胰岛胰高血糖素分泌的全身性抑制剂
研究探索GLP-1代谢物GLP-1(9-36)对胰岛胰高血糖素分泌的直接抑制作用及其在糖尿病中的变化。在小鼠和人胰岛中发现GLP-1(9-36)通过胰高血糖素受体依赖机制抑制胰高血糖素分泌,该作用在2型糖尿病供体α细胞中丧失,体内高浓度GLP-1(9-36)可降低低血糖时的循环胰高血糖素。
要点
- GLP-1(7-36)抑制离体胰岛胰高血糖素分泌的IC50为2.5 pmol/l,低糖时作用更强。
- GLP-1(9-36)经胰高血糖素受体依赖途径抑制胰高血糖素分泌,该作用在2型糖尿病供体α细胞中丧失。
- 体内高浓度GLP-1(9-36)(>100 pmol/l)使胰岛素诱导低血糖时循环胰高血糖素降低30%。
核心结论
- GLP-1代谢物GLP-1(9-36)是胰高血糖素分泌的全身性抑制剂。
- 小鼠中遗传/药理失活胰高血糖素信号及2型糖尿病患者中观察到的循环胰高血糖素升高,可能反映GLP-1(9-36)胰高血糖素抑制作用的去除。
研究设计与样本
- 结合小鼠和人胰岛(包括2型糖尿病供体胰岛)的胰高血糖素分泌测定、全内反射荧光显微镜成像分泌颗粒动力学、胞质Ca2+和蛋白激酶A活性记录、免疫细胞化学、在体生理学和GTP结合蛋白解离研究。
主要发现
- GLP-1(7-36)抑制离体胰岛胰高血糖素分泌的IC50为2.5 pmol/l,低葡萄糖浓度时作用尤其强,降解产物GLP-1(9-36)具有相同能力。
- GLP-1(9-36)在遗传/药理失活GLP-1受体后仍保留胰高血糖素抑制作用,并有效抑制β-肾上腺素能刺激、氨基酸和膜去极化诱发的胰高血糖素分泌。
- 在胰岛α细胞中,GLP-1(9-36)抑制经对ω-阿加毒素敏感的电压门控Ca2+通道的Ca2+内流,导致对百日咳毒素敏感的锚定分泌颗粒池耗竭,这些效应被胰高血糖素受体拮抗剂REMD2.59和L-168049阻止。
- GLP-1(9-36)抑制胰高血糖素分泌和减少锚定颗粒数量的能力在2型糖尿病供体α细胞中丧失。
- 在体内,高外源性浓度GLP-1(9-36)(>100 pmol/l)使胰岛素诱导低血糖时循环胰高血糖素降低30%,该效应被REMD2.59消除,后者使循环胰高血糖素迅速升高>225%(经血浆葡萄糖变化校正),而不影响胰腺胰高血糖素含量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetes mellitus is associated with impaired insulin secretion, often aggravated by oversecretion of glucagon. Therapeutic interventions should ideally correct both defects. Glucagon-like peptide 1 (GLP-1) has this capability but exactly how it exerts its glucagonostatic effect remains obscure. Following its release GLP-1 is rapidly degraded from GLP-1(7-36) to GLP-1(9-36). We hypothesised that the metabolite GLP-1(9-36) (previously believed to be biologically inactive) exerts a direct inhibitory effect on glucagon secretion and that this mechanism becomes impaired in diabetes. METHODS: We used a combination of glucagon secretion measurements in mouse and human islets (including islets from donors with type 2 diabetes), total internal reflection fluorescence microscopy imaging of secretory granule dynamics, recordings of cytoplasmic Ca2+ and measurements of protein kinase A activity, immunocytochemistry, in vivo physiology and GTP-binding protein dissociation studies to explore how GLP-1 exerts its inhibitory effect on glucagon secretion and the role of the metabolite GLP-1(9-36). RESULTS: GLP-1(7-36) inhibited glucagon secretion in isolated islets with an IC50 of 2.5 pmol/l. The effect was particularly strong at low glucose concentrations. The degradation product GLP-1(9-36) shared this capacity. GLP-1(9-36) retained its glucagonostatic effects after genetic/pharmacological inactivation of the GLP-1 receptor. GLP-1(9-36) also potently inhibited glucagon secretion evoked by β-adrenergic stimulation, amino acids and membrane depolarisation. In islet alpha cells, GLP-1(9-36) led to inhibition of Ca2+ entry via voltage-gated Ca2+ channels sensitive to ω-agatoxin, with consequential pertussis-toxin-sensitive depletion of the docked pool of secretory granules, effects that were prevented by the glucagon receptor antagonists REMD2.59 and L-168049. The capacity of GLP-1(9-36) to inhibit glucagon secretion and reduce the number of docked granules was lost in alpha cells from human donors with type 2 diabetes. In vivo, high exogenous concentrations of GLP-1(9-36) (>100 pmol/l) resulted in a small (30%) lowering of circulating glucagon during insulin-induced hypoglycaemia. This effect was abolished by REMD2.59, which promptly increased circulating glucagon by >225% (adjusted for the change in plasma glucose) without affecting pancreatic glucagon content. CONCLUSIONS/INTERPRETATION: We conclude that the GLP-1 metabolite GLP-1(9-36) is a systemic inhibitor of glucagon secretion. We propose that the increase in circulating glucagon observed following genetic/pharmacological inactivation of glucagon signalling in mice and in people with type 2 diabetes reflects the removal of GLP-1(9-36)'s glucagonostatic action.
引用
- Gandasi NR, Gao R, Kothegala L, et al. GLP-1 metabolite GLP-1(9-36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion. Diabetologia. 2023. PMID: 38127123. doi:10.1007/s00125-023-06060-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。